NEW YORK (GenomeWeb) – Sygnis today announced a non-exclusive distribution agreement with Sopachem for the commercialization of TruePrime products.

Under the terms of the agreement, Sopachem will promote, market, sell, and support TruePrime products for primer-free whole genome amplification in Belgium.

TruePrime products use Sygnis' multiple displacement amplification technology based on DNA primase TthPrimPol and Phi29 polymerase.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.